{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:52:18Z","timestamp":1793238738011,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda Pharmaceuticals International AG \u2013 Singapore Branch"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Brentuximab vedotin (BV) as post-autologous stem cell transplantation (ASCT) consolidation was shown to reduce the relapse risk among high-risk patients with relapsed\/refractory Hodgkin lymphoma (RRHL) in the clinical trial setting. This systematic review and meta-analysis characterizes real-world evidence (RWE) on the effectiveness and safety of BV as post-ASCT consolidation in 1504 adult and pediatric patients with RRHL from 23 studies across 17 countries. A random-effects model yielded pooled progression-free survival (PFS) and overall survival rates (OS); PFS: 2-year, 74.2%; 5-year, 65.8%; OS: 2-year, 95.8%; 5-year, 91.9%. The most common any-grade adverse events were neuropathy (34.2%) and neutropenia (20.2%). Despite heterogeneity in populations and outcomes, this analysis utilizing real-world data corroborates the efficacy and safety of BV as post-ASCT consolidation in RRHL reported in the experimental arm of the Phase III AETHERA trial. The favorable PFS results in cases exposed to BV prior to ASCT indicate the value of BV in controlling Hodgkin lymphoma (HL) in the salvage setting. Continued research is essential to refine BV treatment strategies amid the evolving treatment landscape.<\/jats:p>","DOI":"10.1038\/s41409-025-02557-7","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T18:32:25Z","timestamp":1744137145000},"page":"820-831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed\/refractory Hodgkin lymphoma: A systematic review and meta-analysis"],"prefix":"10.1038","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Pavlovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalah","family":"Haidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fjoralba","family":"Kristo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Stache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Zomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"2557_CR1","doi-asserted-by":"publisher","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","volume":"18","author":"RT Hoppe","year":"2020","unstructured":"Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, et al. Hodgkin lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18:755\u201381.","journal-title":"J Natl Compr Canc Netw"},{"key":"2557_CR2","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","volume":"27","author":"A Engert","year":"2009","unstructured":"Engert A, Diehl V, Franklin J, Lohri A, Dorken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin\u2019s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27:4548\u201354.","journal-title":"J Clin Oncol"},{"key":"2557_CR3","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","volume":"31","author":"LI Gordon","year":"2013","unstructured":"Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013;31:684\u201391.","journal-title":"J Clin Oncol"},{"key":"2557_CR4","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","volume":"34","author":"P Carde","year":"2016","unstructured":"Carde P, Karrasch M, Fortpied C, Brice P, Khaled H, Casasnovas O, et al. Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score >\/= 3, high-risk Hodgkin lymphoma: first results of the Phase III EORTC 20012 Intergroup Trial. J Clin Oncol 2016;34:2028\u201336.","journal-title":"J Clin Oncol"},{"key":"2557_CR5","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2017","unstructured":"Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, et al. PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017;390:2790\u2013802.","journal-title":"Lancet"},{"key":"2557_CR6","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2206125","volume":"387","author":"SM Ansell","year":"2022","unstructured":"Ansell SM, Radford J, Connors JM, Dlugosz-Danecka M, Kim WS, Gallamini A, et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2022;387:310\u201320.","journal-title":"N Engl J Med"},{"key":"2557_CR7","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","volume":"57","author":"JA Snowden","year":"2022","unstructured":"Snowden JA, Sanchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transpl. 2022;57:1217\u201339.","journal-title":"Bone Marrow Transpl"},{"key":"2557_CR8","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Hodgkin Lymphoma V.3.2024 2024 [updated March 18, 2024; cited 2025 February 11]. Available from: https:\/\/www.nccn.org."},{"key":"2557_CR9","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.bbmt.2006.06.006","volume":"12","author":"NS Majhail","year":"2006","unstructured":"Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin\u2019s lymphoma. Biol Blood Marrow Transpl. 2006;12:1065\u201372.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2557_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2141.2011.08616.x","volume":"153","author":"SD Smith","year":"2011","unstructured":"Smith SD, Moskowitz CH, Dean R, Pohlman B, Sobecks R, Copelan E, et al. Autologous stem cell transplant for early relapsed\/refractory Hodgkin lymphoma: results from two transplant centres. Br J Haematol. 2011;153:358\u201363.","journal-title":"Br J Haematol"},{"key":"2557_CR11","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","volume":"54","author":"S Arai","year":"2013","unstructured":"Arai S, Fanale M, DeVos S, Engert A, Illidge T, Borchmann P, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54:2531\u20133.","journal-title":"Leuk Lymphoma"},{"key":"2557_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/annonc\/mdi119","volume":"16","author":"A Sureda","year":"2005","unstructured":"Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse. Ann Oncol. 2005;16:625\u201333.","journal-title":"Ann Oncol"},{"key":"2557_CR13","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/bmt.2017.143","volume":"52","author":"M Damlaj","year":"2017","unstructured":"Damlaj M, Ghazi S, Syed G, Pasha T, Gmati G, Salama H, et al. Pre-autologous transplantation PET\/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma. Bone Marrow Transpl. 2017;52:1342\u20134.","journal-title":"Bone Marrow Transpl"},{"key":"2557_CR14","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","volume":"28","author":"PJ Brockelmann","year":"2017","unstructured":"Brockelmann PJ, Muller H, Casasnovas O, Hutchings M, von Tresckow B, Jurgens M, et al. Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2017;28:1352\u20138.","journal-title":"Ann Oncol"},{"key":"2557_CR15","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853\u201362.","journal-title":"Lancet"},{"key":"2557_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27962","volume":"66","author":"JE Flerlage","year":"2019","unstructured":"Flerlage JE, von Buttlar X, Krasin M, Triplett B, Kaste SC, Metzger ML. Brentuximab vedotin as consolidation after hematopoietic cell transplant for relapsed Hodgkin lymphoma in pediatric patients. Pediatr Blood Cancer. 2019;66:e27962.","journal-title":"Pediatr Blood Cancer"},{"key":"2557_CR17","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/hon.2645","volume":"37","author":"I Sakellari","year":"2019","unstructured":"Sakellari I, Gavriilaki E, Iskas M, Bousiou Z, Chatziioannidis A, Batsis I, et al. Brentuximab vedotin and anti-PD1 treatment optimize survival in chemo-refractory Hodgkin lymphoma patients: Real-world data. Hematol Oncol. 2019;37:490\u20132.","journal-title":"Hematol Oncol"},{"key":"2557_CR18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.24953\/turkjped.2019.05.005","volume":"61","author":"N Tacyildiz","year":"2019","unstructured":"Tacyildiz N, Tanyildiz HG, Unal E, Dincaslan H, Asarcikli F, Aksoy BA, et al. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation. Turk J Pediatr. 2019;61:671\u20136.","journal-title":"Turk J Pediatr"},{"key":"2557_CR19","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1080\/10428194.2020.1728755","volume":"61","author":"J Kort","year":"2020","unstructured":"Kort J, Chidiac A, El Sayed R, Massoud R, Nehme R, Bazarbachi A, et al. Safety and efficacy of four cycles of brentuximab vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed\/refractory Hodgkin lymphoma. Leuk Lymphoma. 2020;61:1732\u20135.","journal-title":"Leuk Lymphoma"},{"key":"2557_CR20","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/hon.2897","volume":"39","author":"OM Akay","year":"2021","unstructured":"Akay OM, Ozbalak M, Pehlivan M, Yildiz B, Uzay A, Yigenoglu TN, et al. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study. Hematol Oncol. 2021;39:498\u2013505.","journal-title":"Hematol Oncol"},{"key":"2557_CR21","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1097\/MPH.0000000000001703","volume":"43","author":"KS Fernandez","year":"2021","unstructured":"Fernandez KS, Mavers M, Marks LJ, Agarwal R. Brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in children and adolescents (<18 y) with early relapse Hodgkin lymphoma. J Pediatr Hematol Oncol. 2021;43:e191\u20134.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2557_CR22","doi-asserted-by":"publisher","first-page":"e929","DOI":"10.1016\/j.clml.2021.07.006","volume":"21","author":"M Kedmi","year":"2021","unstructured":"Kedmi M, Khaustov P, Ribakovsy E, Benjamini O, Avigdor A. Outcomes related to FDG-PET-CT response in patients with Hodgkin lymphoma treated with brentuximab-vedotin at relapse or consolidation. Clin Lymphoma Myeloma Leuk. 2021;21:e929\u201337.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2557_CR23","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3324\/haematol.2021.279564","volume":"107","author":"A Marouf","year":"2022","unstructured":"Marouf A, Cottereau AS, Kanoun S, Deschamps P, Meignan M, Franchi P, et al. Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study. Haematologica. 2022;107:1681\u20136.","journal-title":"Haematologica"},{"key":"2557_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29801","volume":"69","author":"D Massano","year":"2022","unstructured":"Massano D, Carraro E, Mussolin L, Buffardi S, Barat V, Zama D, et al. Brentuximab vedotin in the treatment of paediatric patients with relapsed or refractory Hodgkin\u2019s lymphoma: Results of a real-life study. Pediatr Blood Cancer. 2022;69:e29801.","journal-title":"Pediatr Blood Cancer"},{"key":"2557_CR25","doi-asserted-by":"publisher","first-page":"982","DOI":"10.3390\/cancers14040982","volume":"14","author":"F Massaro","year":"2022","unstructured":"Massaro F, Meuleman N, Bron D, Vercruyssen M, Maerevoet M. Brentuximab vedotin and pembrolizumab combination in patients with relapsed\/refractory Hodgkin lymphoma: A single-centre retrospective analysis. Cancers. 2022;14:982.","journal-title":"Cancers"},{"key":"2557_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/hon.2939","volume":"40","author":"F Massaro","year":"2022","unstructured":"Massaro F, Pavone V, Stefani PM, Botto B, Pulsoni A, Patti C, et al. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. Hematol Oncol. 2022;40:31\u20139.","journal-title":"Hematol Oncol"},{"key":"2557_CR27","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/bloodadvances.2022009323","volume":"7","author":"CJ Forlenza","year":"2023","unstructured":"Forlenza CJ, Rosenzweig J, Mauguen A, Buhtoiarov I, Cuglievan B, Dave H, et al. Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed\/refractory Hodgkin lymphoma. Blood Adv. 2023;7:3225\u201331.","journal-title":"Blood Adv"},{"key":"2557_CR28","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1007\/s00277-023-05354-8","volume":"102","author":"K Husi","year":"2023","unstructured":"Husi K, Szabo R, Pinczes LI, Foldeak D, Dudley R, Szomor A, et al. Improved survival of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma in the brentuximab vedotin era - real-world data from Hungary. Ann Hematol. 2023;102:2555\u201363.","journal-title":"Ann Hematol"},{"key":"2557_CR29","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00277-022-05011-6","volume":"102","author":"C Martinez","year":"2023","unstructured":"Martinez C, de Haro ME, Romero S, Gutierrez A, Domingo-Domenech E, Gonzalez-Rodriguez AP, et al. Impact of pre- and\/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma. Ann Hematol. 2023;102:429\u201337.","journal-title":"Ann Hematol"},{"key":"2557_CR30","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.3324\/haematol.2023.282780","volume":"108","author":"CB Wagner","year":"2023","unstructured":"Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, et al. Effect of cumulative dose of brentuximab vedotin maintenance in relapsed\/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica. 2023;108:3025\u201332.","journal-title":"Haematologica"},{"key":"2557_CR31","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/s41409-023-02036-x","volume":"58","author":"M Damlaj","year":"2023","unstructured":"Damlaj M, Tlayjeh M, Damlaj A, Alahmari B, AlSadi H, Ahmed M, et al. Contemporary outcomes of high risk relapsed refractory classical Hodgkin lymphoma patients-role of maintenance therapy in the real world. Bone Marrow Transpl. 2023;58:1160\u20132.","journal-title":"Bone Marrow Transpl"},{"key":"2557_CR32","doi-asserted-by":"publisher","first-page":"S324","DOI":"10.1016\/j.clml.2017.07.132","volume":"17","author":"L Arag\u00e3o","year":"2017","unstructured":"Arag\u00e3o L, Bispo O, Carvalho H, Silva A, Souza V, Carvalho L, et al. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin\u2019s lymphoma: The real world experience of a single bone marrow transplant center in Salvador\/Bahia. Clin Lymphoma Myeloma Leuk. 2017;17:S324.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2557_CR33","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.1182\/blood-2019-129295","volume":"134","author":"B Pati\u00f1o","year":"2019","unstructured":"Pati\u00f1o B, Acon-Solano C, Pereira M, Enciso-Olivera L, Hoz DO-DL, Cordero, et al. Brentuximab vedotin as consolidation therapy post hematopoietic stem cell transplantation for patients with relapsed or refractory Hodgkin lymphoma: A real world analysis of the Colombian experience. Blood. 2019;134:5275.","journal-title":"Blood"},{"key":"2557_CR34","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1182\/blood-2021-154492","volume":"138","author":"S Chung","year":"2021","unstructured":"Chung S, White J, Toze CL, Sutherland HJ, Sanford D, Rodrigo JA, et al. Autologous stem cell transplant outcome in classic Hodgkin lymphoma patients in the era of post-transplant brentuximab vedotin consolidation. Blood. 2021;138:3935.","journal-title":"Blood"},{"key":"2557_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/01.HS9.0000890984.54786.aa","volume":"6","author":"Michalka","year":"2022","unstructured":"Michalka, Markov\u00e1 J, Gah\u00e9rov\u00e1 J, Maco M, Proch\u00e1zka V, Ko\u0159en J, et al. P104: Consolidation therapy with brentuximab vedotin after autologous stem cell transplantation for relapsed\/refractory Hodgkin lymphoma in the Czech Republic. HemaSphere. 2022;6:48\u20139.","journal-title":"HemaSphere"},{"key":"2557_CR36","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.1182\/blood-2022-167644","volume":"140","author":"MCM Munoz","year":"2022","unstructured":"Munoz MCM, Bastos-Oreiro M, Boumendil A, Finel H, Bazarbachi A, Alzahrani M, et al. Real life analysis of brentuximab vedotin (BV) use as consolidation therapy in patients with Hodgkin\u2019s lymphoma (HL) with high risk of relapse after autologous stem cell transplantation (ASCT). A retrospective analysis of the EBMT Lymphoma Working Party. Blood. 2022;140:6558\u201360.","journal-title":"Blood"},{"key":"2557_CR37","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1182\/blood-2023-182318","volume":"142","author":"AS Falade","year":"2023","unstructured":"Falade AS, Redd RA, Shah H, Baron K, Iyengar S, Desai SH, et al. Efficacy of brentuximab vedotin maintenance therapy following autologous stem cell transplantation in patients with relapsed\/refractory classical Hodgkin lymphoma with and without pre-transplant exposure to novel agents. Blood. 2023;142:3062.","journal-title":"Blood"},{"key":"2557_CR38","first-page":"3839","volume":"8","author":"L Fiad","year":"2024","unstructured":"Fiad L, Warley F, Altuve JG, Cerutti A, Salvano L, Guanchiale L, et al. Prospective real-world evidence of brentuximab vedotin (BV) consolidation after autologous hematopoietic stem cell transplantation (ASCT) in patients with relapsed\/refractory Hodgkin lymphoma (RR HL). HemaSphere. 2024;8:3839\u201340.","journal-title":"HemaSphere"},{"key":"2557_CR39","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"2557_CR40","unstructured":"The Joanna Briggs Institute. Critical appraisal tools [cited 2025 February 11]. Available from: https:\/\/jbi.global\/critical-appraisal-tools."},{"key":"2557_CR41","doi-asserted-by":"publisher","first-page":"478","DOI":"10.11124\/JBIES-22-00125","volume":"21","author":"TH Barker","year":"2023","unstructured":"Barker TH, Stone JC, Sears K, Klugar M, Leonardi-Bee J, Tufanaru C, et al. Revising the JBI quantitative critical appraisal tools to improve their applicability: an overview of methods and the development process. JBI Evid Synth. 2023;21:478\u201393.","journal-title":"JBI Evid Synth"},{"key":"2557_CR42","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","volume":"132","author":"CH Moskowitz","year":"2018","unstructured":"Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639\u201342.","journal-title":"Blood"},{"key":"2557_CR43","unstructured":"Takeda Pharmaceuticals. Adcetris\u00ae (brentuximab vedotin). Prescribing Information. 2022 [updated November 2022; cited 2025 February 11]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125388s106lbl.pdf."},{"key":"2557_CR44","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1182\/blood-2024-205007","volume":"144","author":"MCM Munoz","year":"2024","unstructured":"Munoz MCM, Khvedelidze I, Fekom M, Fischer BD, Marouf A, Ghesquieres H, et al. Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group. Blood. 2024;144:1663.","journal-title":"Blood"},{"key":"2557_CR45","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","volume":"21","author":"R Chen","year":"2015","unstructured":"Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, et al. Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory Hodgkin lymphoma. Biol Blood Marrow Transpl. 2015;21:2136\u201340.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2557_CR46","doi-asserted-by":"publisher","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","volume":"17","author":"J Katz","year":"2011","unstructured":"Katz J, Janik JE, Younes A. Brentuximab Vedotin (SGN-35). Clin Cancer Res. 2011;17:6428\u201336.","journal-title":"Clin Cancer Res"},{"key":"2557_CR47","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.2147\/OTT.S141053","volume":"11","author":"EM Donato","year":"2018","unstructured":"Donato EM, Fernandez-Zarzoso M, Hueso JA, de la Rubia J. Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review. Onco Targets Ther. 2018;11:4583\u201390.","journal-title":"Onco Targets Ther"},{"key":"2557_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07561-2","volume":"20","author":"A Sureda","year":"2020","unstructured":"Sureda A, Andre M, Borchmann P, da Silva MG, Gisselbrecht C, Vassilakopoulos TP, et al. Improving outcomes after autologous transplantation in relapsed\/refractory Hodgkin lymphoma: a European expert perspective. BMC Cancer. 2020;20:1088.","journal-title":"BMC Cancer"},{"key":"2557_CR49","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/j.1365-2141.2009.08037.x","volume":"148","author":"CH Moskowitz","year":"2010","unstructured":"Moskowitz CH, Yahalom J, Zelenetz AD, Zhang Z, Filippa D, Teruya-Feldstein J, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol. 2010;148:890\u20137.","journal-title":"Br J Haematol"},{"key":"2557_CR50","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3324\/haematol.2021.278311","volume":"107","author":"Y Nieto","year":"2021","unstructured":"Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, et al. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: A 15-year analysis. Haematologica. 2021;107:899.","journal-title":"Haematologica"},{"key":"2557_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-021-08225-5","volume":"21","author":"K Noring","year":"2021","unstructured":"Noring K, Carlsten M, Sonnevi K, Wahlin BE. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome. BMC Cancer. 2021;21:1\u201312.","journal-title":"BMC Cancer"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02557-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02557-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02557-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T15:02:03Z","timestamp":1749567723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02557-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2557"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02557-7","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Anna Sureda reports honoraria from Takeda Pharmaceuticals, Bristol Myers Squibb\/Celgene, Merck Sharp & Dohme, Janssen, Amgen, Novartis, Kite\/Gilead, Sanofi, Roche, and Alexion; consultancy for Takeda Pharmaceuticals, Bristol Myers Squibb\/Celgene, Novartis, Janssen, Gilead, and Sanofi; speakers bureau for Takeda Pharmaceuticals; research support from Takeda Pharmaceuticals and Bristol Myers Squibb\/Celgene; and Presidency of the European Society for Blood and Marrow Transplantation. Astrid Pavlovsky reports grants or contracts from Takeda Pharmaceuticals; consulting fees from Takeda Pharmaceuticals, Bristol Myers Squibb, and Merck Sharp & Dohme; and support from Roche and Takeda Pharmaceuticals to attend meetings. Dalah Haidar, Fjoralba Kristo, Vanessa Stache, and Athanasios Zomas are employees of Takeda Pharmaceuticals and hold shares in the company.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}